Jefferies Downgrades PTC Therapeutics to Hold, Lowers Price Target to $76
Benzinga Newsdesk 7 months ago
NewsDowngradesPrice TargetAnalyst Ratings
Jefferies analyst Faisal Khurshid downgrades PTC Therapeutics (NASDAQ:PTCT) from Buy to Hold and lowers the price target from $91 to $76.
Jefferies analyst Faisal Khurshid downgrades PTC Therapeutics (NASDAQ:PTCT) from Buy to Hold and lowers the price target from $91 to $76.